PharmaEngine Announces Taiwan FDA Approval of ONIVYDE (TM) (irinotecan liposome injection) for the Treatment of Metastatic Pancreatic Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. ANET
3. NKE
4. PANW
5. CL
6. SNDK
7. TAP
8. DELL
9. ROIV
10. HONA

Go back to PharmaEngine Announces Taiwan FDA Approval of ONIVYDE (TM) (irinotecan liposome injection) for the Treatment of Metastatic Pancreatic Cancer

Merrimack Pharma (MACK) Drops Lower Following ONIVYDE Approval; Will Include 'Boxed Warning'

October 22, 2015 2:10 PM EDT

Merrimack (Nasdaq: MACK) shares are down over 21 percent with heavy volume Thursday afternoon after the company... More

FDA Approves Merrimack Pharma's (MACK) ONIVYDE

October 22, 2015 11:32 AM EDT

(Updated - October 22, 2015 11:35 AM EDT)

The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.

According to the National Cancer Institute, there will be 48,960 new cases of pancreatic cancer diagnosed in the U.S. in 2015, and nearly the same number of deaths caused by the disease (40,560). Pancreatic cancer can be difficult to diagnose early and treatment options are limited, especially when the disease has spread to other parts of the body (metastatic... More